Cytokinetics vs Recursion Pharmaceuticals
Cytokinetics is the larger business, with $88.0m of revenue in fiscal 2025 against $74.7m for Recursion Pharmaceuticals (1.2 times as much). Cytokinetics grew faster (376.6% against 26.9%). Recursion Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -863.4% against -891.6%.
| Latest fiscal year | CytokineticsCYTK, 2025 | Recursion PharmaceuticalsRXRX, 2025 |
|---|---|---|
| Revenue | $88.0m | $74.7m |
| Revenue growth | 376.6% | 26.9% |
| Net income | −$785m | −$645m |
| Operating margin | -695.4% | -867.9% |
| Net margin | -891.6% | -863.4% |
| Return on equity | — | -59.5% |
| Free cash flow | −$535m | −$378m |
| Cash | $123m | $743m |
| Total debt | $999m | $18.7m |
| Debt to equity | — | 1.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 673 | — |
| Market value | $7.69bn | $2.10bn |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 85 sales | 0 buys, 35 sales |